Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Shock ; 61(6): 836-840, 2024 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-38713552

RESUMEN

ABSTRACT: Objective: This study aimed to investigate the effect of the central venous-to-arterial carbon dioxide partial pressure difference (Pcv-aCO2) on the administration of cardiotonic drugs in patients with early-stage septic shock. Methods: A retrospective study was conducted on 120 patients suffering from septic shock. At admission, the left ventricular ejection fraction (LVEF) and Pcv-aCO2 of the patients were obtained. On the premise of mean arterial pressure ≥ 65 mm Hg, the patients were divided into two groups according to the treatment approaches adopted by different doctors-control group: LVEF ≤50% and observation group: Pcv-aCO2 ≥ 6. Both groups received cardiotonic therapy. Results: The two groups of patients had similar general conditions and preresuscitation conditions ( P > 0.05). Compared with the control group, the observation group had a higher mean arterial pressure, lactic acid clearance rate, and urine output after 6 h of resuscitation ( P < 0.05), but a lower absolute value of lactic acid, total fluid intake in 24 h, and a lower number of patients receiving renal replacement therapy during hospitalization ( P < 0.05). After 6 hours of resuscitation, the percentages of patients meeting central venous oxygen saturation and central venous pressure targets were not significantly different between the control and observation groups ( P > 0.05). There was no difference in the 28-day mortality rate between the two groups ( P > 0.05). Conclusion: Pcv-aCO2 is more effective than LVEF in guiding the administration of cardiotonic drugs in the treatment of patients with septic shock.


Asunto(s)
Dióxido de Carbono , Cardiotónicos , Presión Venosa Central , Choque Séptico , Humanos , Choque Séptico/tratamiento farmacológico , Choque Séptico/terapia , Masculino , Femenino , Estudios Retrospectivos , Dióxido de Carbono/sangre , Anciano , Persona de Mediana Edad , Cardiotónicos/uso terapéutico , Presión Parcial
2.
Biomed Environ Sci ; 31(4): 311-316, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29773095

RESUMEN

Exposure to free silica induces silicosis and myofibroblasts are regarded as primary effector cells. Fibrocytes can differentiate into myofibroblast. Therefore, the present study was designed to investigate whether fibrocytes participate in silicosis. The rat model of silicosis was established. Hematoxylin-eosin stainings and Masson stainings were used to evaluate the histopathology and collagen deposition. Flow cytometry and immunofluorescence were performed to detect the number of fibrocytes and their contribution to myofibroblasts. Results showed that fibrocytes participate in silicosis. Trend analysis of different sources of myofibroblasts during silicosis indicated that fibrocytes and lung type II epithelial cell-derived myofibroblasts play an important role in the early stage of silicosis, while resident lung fibroblast-derived myofibroblasts play a predominant role during the fibrosis formative period.


Asunto(s)
Pulmón/citología , Miofibroblastos/efectos de los fármacos , Dióxido de Silicio/toxicidad , Silicosis/etiología , Animales , Modelos Animales de Enfermedad , Miofibroblastos/patología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Silicosis/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA